Development Program Diligence Sample Clauses

Development Program Diligence. For each Selected Target, Lilly Companies agrees to use its Commercially Reasonable Efforts to complete the Development Program for at least one (1) Product in the Field in at least the United States and one other Major Market country. Lilly Companies agrees that it shall perform the Development Program in a professional manner with reasonable skill and care, using suitably qualified personnel, and without providing any warranties of success and will use its Commercially Reasonable Efforts to achieve the objectives of the Development Program. Lilly Companies will undertake all activities under this Agreement in accordance with all applicable Laws and, as applicable, using Good Research Practices, Good Laboratory Practices, Good Clinical Practices and Good Manufacturing Agreements. Lilly Companies shall be responsible for the acts and omissions of any sub-contractor which it engages, as if such acts or omissions had been made by themselves. For purposes of clarity, at such time as any Lilly Company has commercially launched at least one Product in accordance with Section 4.1, regardless of the number of Selected Targets, Lilly Companies’ obligations under this Article 4 shall cease and have no further legal effect (“CRE Termination Date”).
View Source
Development Program Diligence 
View Source

Related to Development Program Diligence

  • Development Diligence Pfizer will use its Commercially Reasonable Efforts to Develop and seek Regulatory Approval for one Product in the Field in [***]. Pfizer will have no other diligence obligations with respect to the Development or Regulatory Approval of Products under this Agreement.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Research Program The term “

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).